Genprex, Inc. (NASDAQ:GNPX) Sees Significant Drop in Short Interest

Genprex, Inc. (NASDAQ:GNPX) saw a large decline in short interest in the month of March. As of March 15th, there was short interest totalling 333,600 shares, a decline of 47.3% from the February 28th total of 633,100 shares. Approximately 4.0% of the shares of the company are sold short. Based on an average trading volume of 1,830,000 shares, the days-to-cover ratio is currently 0.2 days.

Hedge Funds Weigh In On Genprex

An institutional investor recently raised its position in Genprex stock. Geode Capital Management LLC grew its holdings in Genprex, Inc. (NASDAQ:GNPX) by 368.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 76,045 shares of the company’s stock after purchasing an additional 59,798 shares during the period. Geode Capital Management LLC owned about 0.89% of Genprex worth $65,000 as of its most recent filing with the Securities & Exchange Commission. 14.05% of the stock is currently owned by institutional investors.

Genprex Trading Down 21.1 %

Genprex stock traded down $0.07 during mid-day trading on Friday, hitting $0.27. The stock had a trading volume of 3,612,556 shares, compared to its average volume of 3,047,860. The firm’s 50 day moving average is $0.45 and its 200 day moving average is $0.81. Genprex has a one year low of $0.25 and a one year high of $4.09.

About Genprex

Genprex, Inc, a clinical-stage gene therapy company, focuses on developing gene-based therapies for patients with cancer and diabetes in the United States. The company's lead product candidate is REQORSA (GPX-001), which is in preclinical trials to treat non-small cell lung cancer and small cell lung cancer; and GPX-002, which is in preclinical trials to treat type 1 and type 2 diabetes.